HPLC method for quantification of ornidazole in human plasma

Asian Journal of Chemistry

Volumn 20, Issue 6, 2008, Pages 4361-4368

  Sam Solomon, W D ^a   Veeran Gowda, K ^a   Senthamil Selvan, P ^a   Mandal, U ^a   Pal, T K ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Bioequivalence; HPLC; Human plasma; Ornidazole

Indexed keywords

EID: 54049128950     PISSN: 09707077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. R.M. McClain and J.C. Downing, Toxicol. Appl. Pharmacol., 92, 480 (1988).
2. Martindale, The Extra Pharmacopoeia, in ed.: J.E.F. Reynolds, Royal Pharmaceutical Society, London, edn. 32, pp. 589-590 (1999).
3. D.E. Schwartz and F. Jeunet, Chemotherapy, 22, 19 (1976).
4. L. Jokipii and A.M.M. Jokipii, Gastroenterology, 83, 399 (1982).
5. P.O. Eranko, E.S. Palva, K. Konno and V.M.K. Venho, Pharmaceutic. Med., 4, 197 (1990).
6. J. Emami, J. Varshosaz, M. Flamarzian and R. Tahvilian, J. Pharm. Biomed. Anal., 33, 513 (2003).
7. L. Qin and J.C. Min, Chin. J. Mod. Appl. Pharm., 2, 129 (2004).
8. S. Annick, E.J. Bernadet, V.B. Marc, B. Francis, P.B. Jean, B. Karim and C. Jean, Antimicrob. Agents Chemother., 37, 1873 (1993).
9. M.S. Shekar, V. Vidyasagar. N. Narsaiah, R. Anandkumar and D.R. Krishna, Indian J. Pharm. Sci., 67, 302 (2005).
10. K. Rona and B.G. Simple, J. Chromatogr, 420, 228 (1987).
11. B. Monika, S. Baljinder, S. Amarjit and S. Saranjit, J. Pharm. Biomed. Anal., 26, 891 (2001).
12. A. Turcant, J.C. Granry, P. Allain and M. Cavellat, Eur. J. Clin. Pharmacol., 32, 111 (1987).
13. H. Jianquan, C. Guoying, H. Xin, S. Chunhua and Z. Junren, Chirality, 18, 587 (2006).
14. S. Natarajan and B. Raman, The Indian Pharm., 4, 79 (2005).
15. V.P. Shah, K.K. Midha and S. Sighe, Eur. J. Drug. Metab. Pharmacokin., 16, 249 (1992).
16. R.L. Nation and L.N. Sansom, Pharmacol. Ther., 62, 41 (1994).
17. S. Chow, Drug. Lnf. J., 33, 435 (1999).
18. M.D. Rockville, FDA Guidance on Statistical Procedures for Bioequivalence Studies using a Standard Two-Treatment Crossover Designs, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration (1992).
19. W.J. Westlake, J. Pharm. Sci., 61, 1340 (1972).